Three cases of secondary leukemia. Clinicopathologic findings.
Three cases of secondary leukemia developing after chemotherapy and/or radiotherapy for myeloma, mycosis fungoides, and non-Hodgkin's lymphoma are reported. The first case was a 51-year-old man with IgG-lambda myeloma, treated with melphalan and prednisolone, who developed acute myelomonocytic leukemia 54 months after the diagnosis of myeloma. The second case was a 54-year-old woman with mycosis fungoides treated with radiation, predonine, and cyclophosphamide, who developed acute megakaryoblastic leukemia 298 months after the diagnosis of mycosis fungoides. The third case was a 35-year-old woman with stage IV non-Hodgkin's lymphoma treated with VEMP who developed acute myelogenous leukemia 26 months after the diagnosis of malignant lymphoma. All cases showed pancytopenia and two of three cases had morphologic abnormality in several hemopoietic cell lineages in the leukemic stage. There is a possibility that second malignancies are an increasingly recognized complication in the patients treated with a large amount of chemo-radiotherapy.
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007938:Leukemia / Q000139:chemically induced / Q000209:etiology* / Q000473:pathology; D007947:Leukemia, Megakaryoblastic, Acute / Q000139:chemically induced / Q000209:etiology; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced; D007953:Leukemia, Radiation-Induced / Q000473:pathology*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008558:Melphalan / Q000009:adverse effects / Q000627:therapeutic use; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000532:radiotherapy; D010198:Pancytopenia / Q000150:complications; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D008558:Melphalan